UK Markets close in 6 hrs 18 mins

4basebio Plc - Director/PDMR Shareholding

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

13 July 2022

4basebio plc
(the "Company")

Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that it was notified on 12 July 2022 that Dr Heikki Lanckriet, chief executive officer, on the same day transferred 29,000 ordinary shares at a price of 415 pence per share from his personal holding into his SIPP (the “Transfer”).

Following the Transfer, there is no change to Dr Heikki Lanckriet’s beneficial holding, and his interest in the Company remains at 1,252,453 Ordinary Shares, representing approximately 10.17% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio plc

+44 (0)12 2396 7943

Heikki Lanckriet, CEO

Cairn Financial Advisers LLP (Nominated Adviser)

+44 (0)20 7213 0880

Jo Turner / Sandy Jamieson

finnCap Ltd (Broker)

+44 (0)20 7220 0500

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Heikki Lanckriet

2

Reason for notification

a.

Position/Status

Chief Executive Officer

b.

Initial notification/
Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

4basebio plc

b.

LEI

213800E2DX9EAIUNCB30

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares


ISIN: GB00BMCLYF79

b.

Nature of the transaction

Transfer from nominee account to SIPP

c.

Price(s) and volume(s)

Price(s) per share (p)

Volume(s)

415p

29,000

d.

Aggregated information

  • 29,000

  • 415 pence per share

e.

Date of the transaction

12/07/2022

f.

Place of the transaction

London Stock Exchange, AIM

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting